ALB and liver dysplastic nodule: We can only refer here to publicly available information from the data bank (clinicaltrials.gov): Mitsubishi Tanabe Pharma was conducting apararenone for the treatment of diabetic nephropathy (DN) in phase II studies in Eastern Europe and Japan and is currently recruiting for an extended treatment study (28 weeks) in patients with DN (excluding patients with an urinary albumin to creatinine ratio (UACR) of ≥300 mg/g).